Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: Post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

Hiroyoshi Suzuki*, Daniel Castellano, Johann De Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Meredith C. Foster, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Ronald De Wit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: Post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science